Publications:
Our Research

Phase 3 and beyond: The RSV F nanoparticle vaccine for infants via maternal immunization

Severe Morbidity and Mortality Associated with Respiratory Syncytial Virus Versus Influenza Infection in Hospitalized Older Adults

Magnitude and Durability of Anti-F IgG and Palivizumab-Competitive Antibody (PCA) Responses One Year Following Immunization with RSV F NanoparticleV

Progress Towards an Improved Seasonal Influenza Vaccine: NanoFlu - Nanoparticle Influenza Vaccine (NIV)

Why Making a Diagnosis of Respiratory Syncytial Virus Should Matter to Clinicians

Progress Toward a Vaccine for Maternal Immunization to Prevent Respiratory Syncytial Virus (RSV) Lower Respiratory Tract Infection (LRTI) in Infants

Improved Titers against Influenza Drift Variants with a Nanoparticle Vaccine

Data from Completed Phase 1/2 Trial of a Novel Recombinant Saponin-Adjuvanted tNIV

Nanoparticle Influenza Vaccine: Older Adults

RSV F Nanoparticle Vaccine: IVM